Overdose of acetaminophen (APAP) results in acute liver failure. We have investigated the role of a posttranslational modification of proteins called O-GlcNAcylation, where the O-GlcNAc transferase (OGT) adds and O-GlcNAcase (OGA) removes a single b-D-N-acetylglucosamine (O-GlcNAc) moiety, in the pathogenesis of APAP-induced liver injury. Hepatocyte-specific OGT knockout mice (OGT KO), which have reduced O-GlcNAcylation, and wild-type (WT) controls were treated with 300 mg/kg APAP and the development of injury was studied over a time course from 0 to 24 h. OGT KO mice developed significantly lower liver injury as compared with WT mice. Hepatic CYP2E1 activity and glutathione (GSH) depletion following APAP treatment were not different between WT and OGT KO mice. However, replenishment of GSH and induction of GSH biosynthesis genes were significantly faster in the OGT KO mice. Next, male C57BL/6 J mice were treated Thiamet-G (TMG), a specific inhibitor of OGA to induce O-GlcNAcylation, 1.5 h after APAP administration and the development of liver injury was studied over a time course of 0-24 h. TMG-treated mice exhibited significantly higher APAPinduced liver injury. Treatment with TMG did not affect hepatic CYP2E1 levels, GSH depletion, APAP-protein adducts, and APAP-induced mitochondrial damage. However, GSH replenishment and GSH biosynthesis genes were lower in TMGtreated mice after APAP overdose. Taken together, these data indicate that induction in cellular O-GlcNAcylation exacerbates APAP-induced liver injury via dysregulation of hepatic GSH replenishment response.
. In recent years, several types of posttranslational modifications (PTMs), which modulate pathophysiological processes via modifying protein function, have been described in Anbalagan et al. (2012) and Schrattenholz et al. (2010) . However, the role of PTMs in APAP-induced liver injury has not been investigated.
One such PTM is O-GlcNAcylation where a single b-D-N-acetylglucosamine (O-GlcNAc) moiety is added to serine/threonine residues of intracellular proteins (Hart et al., 2007; Hart, 2003, 2011) . Two specific enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), are involved in O-GlcNAc cycling in the cells. OGT catalyzes O-GlcNAcylation using UDP-GlcNAc as the sugar donor, while OGA removes O-GlcNAc from the protein ( Figure 1A ). Extensive studies have demonstrated that O-GlcNAcylation of proteins results in significant changes in protein function and is involved numerous cellular and pathological processes including organ development (Hanover et al., 2012; Liu et al., 2012) , cancer pathogenesis (Slawson and Hart, 2011) , the stress response (Chatham and Marchase, 2010; Martinez et al., 2017) , and cellular proliferation (Slawson et al., 2005 (Slawson et al., , 2010 .
Recently, increased levels of O-GlcNAc via treatment with the potent OGA inhibitor Thiamet G (TMG) have been shown to control tau phosphorylation in the mammalian brain, which could lead to a possible treatment for Alzheimer's disease (Macauley and Vocadlo, 2010) . In the heart, increased levels of O-GlcNAc have been shown to protect cardiomyocytes from injury and decrease inflammation after arterial injury (Champattanachai et al., 2008; Xing et al., 2008) . In the liver, global levels of O-GlcNAc are significantly elevated with hepatocellular carcinoma (Zhu et al., 2012) . However, the effect of changes in hepatic O-GlcNAc levels on APAP toxicity has not been investigated.
In this study, we investigated the effect of O-GlcNAcylation on APAP toxicity using 2 approaches to modulate cellular O-GlcNAc levels in vivo-hepatocyte-specific OGT deletion to decrease O-GlcNAcylation and treatment with TMG, an inhibitor of OGA, to increase the levels of O-GlcNAc. Our data indicate that the alteration of O-GlcNAc levels in the liver can have profound effects on APAP-induced liver injury.
MATERIALS AND METHODS

Animal and Tissue Preparation
All animal studies were approved by and performed in accordance with the Institutional Animal Care and Use Committee at the University of Kansas Medical Center. OGT-floxed mice (Shafi et al., 2000) developed by Dr. Natasha Zachara at The Johns Hopkins School of Medicine were used to generate hepatocyte-specific OGT knockout mice (OGT KO). Two-to three-month-old male OGT-floxed mice (n ¼ 5-7 mice per group per time point) were treated with cre recombinase driven by thyroxin binding globulin promoter carried by the AAV8 virus [AAV8.TBG.PI.Cre.rBG (Penn Vector Core, Philadelphia, Pennsylvania)] at a 5E 11 virus particles administred ip dissolved in 200 microL of saline per mouse 10 days before dosing with APAP. OGT-floxed mice treated with an AAV8 carrying eGFP were used as a control. Using the AAV8-TBG-Cre treatment to delete genes in hepatocyte-specific manner is a standard approach in the liver pathobiology field and has been extensively used (Pradhan-Sundd et al., 2017; Tan et al., 2017; Yanger et al., 2014; Yimlamai et al., 2014) . For experiments with TMG (SD Chemmolecules LLC, Owings Mills, Maryland), 2-to 3-oldmonth male C57BL/6 J mice (n ¼ 3-5 per group per time point) purchased from Jackson Laboratories (Bar Harbor, Maine) were used. All mice were fasted overnight and treated with 300 mg/ kg APAP (Sigma, St Louis, Missouri). APAP was dissolved in warm 0.9% saline and was administered intraperitoneally (i.p.). In acute TMG treatment studies, mice were divided in 2 groups after APAP treatment and injected with either 0.9% saline or 400 mg/kg TMG dissolved in 0.9% saline, ip, 1.5 h after APAP treatment (Supplementary Figure 1A) . In chronic TMG treatment studies, 2-to 3-month old male C57BL/6 J mice were treated with 50 mg/kg TMG every other day for 2 weeks before APAP treatment 24 h after the last TMG dose. In TMG dose finding studies, mice were fasted for 12 h, treated with either 400 or 800 mg/kg TMG dissolved in 0.9% saline and euthanized 18 h after TMG treatment. Livers and blood samples were collected and processed as described before (Borude et al., 2012; Walesky et al., 2013) . Briefly, mice were euthanized by cervical dislocation after anesthesia with isoflorane (Piramal Healthcare, Andhra Pradesh, India) at various time points over a time course of 0-24 h following APAP treatment. Blood and liver were collected. Part of the liver was fixed in 10% neutral buffered formalin and processed to obtain paraffin embedded tissue section, which were stained for H&E and used for histopathological analysis. Serum was separated by centrifugation of blood at 10 000 rpm for 15 min and used for serum ALT activity assay as described before in Borude et al. (2012) .
Staining Procedures
H&E staining was done on a Leica Autostainer XL and CV5030 cover slipper staining was conducted using 4-mm thick paraffin embedded liver samples as described previously in Borude et al. (2012) . Oil Red O staining was performed using 8-mm frozen liver sections as described before in Borude et al. (2012) . Necrosis scoring was performed as previously described in Bhushan et al. (2014) . Briefly, at least 5 high power fields (400Â) were scored in Real Time PCR RNA was isolated using TRIzol (Thermo Fisher Scientific) in accordance with the manufacturer's protocol and converted to cDNA as previously described (Wolfe et al., 2011) . Real time PCR was run on a BioRad CFX384 (Hercules, California) using SYBR green PCR master mix (Applied Biosystems, Foster City, California). All target genes were normalized to 18 S ribosomal RNA and compared with 0 h samples. A comprehensive list of primers can be found in Supplementary Table 2 .
Glutathione Assay and APAP Adduct Measurements Glutathione (GSH) and GSSG were measured in liver homogenates as previously described in Jaeschke and Mitchell (1990) . APAP adducts were measured using HPLC as described before in .
Cyp2E1 Assay
Cyp2E1 activity was measured using a p-nitrophenol assay as described before in Wu and Cederbaum (2008) . Briefly, microsomes were isolated from liver tissue and activity was measured by the hydroxylation of p-nitrophenol to p-nitrocatechol by Cyp2E1.
Mass Spectrometry of APAP Metabolites
Materials. The standards, APAP, 3-(N-acetyl-L-cystein-S-yl) APAP, 4-APAP glucuronide, APAP glutathione, 4-APAP sulfate and 3-cysteinylacetaminophen, and the internal standards, APAP-d 4 and APAP sulfate-d 3 , were purchased from Toronto Research Chemicals (Toronto, Canada). Other chemicals and solvents used were obtained from standard suppliers and were of reagent or analytical grade.
Standard and sample preparation. Stock solutions of APAP and its conjugated metabolites were prepared at 1 mM in 50:50 water:-methanol and stored at À20 C until use. All mouse serum samples were thawed on ice. Several serum samples from untreated mouse were pooled and used as blank matrix for preparation of the calibration curve. A 20 ml aliquot of mouse serum sample was added to 90 ml of methanol (containing 200 ng/ml of APAPd 4 and 400 ng/ml of APAP sulfate-d 3 ) to precipitate the proteins. Then, 70 ml of water and 20 ml of 50:50 water:methanol were added. Samples were vortexed for 10 sec and centrifuged for C. The standards were prepared following the same procedure but replacing the 20 ml of 50:50 water: methanol by 20 ml of working standards in 50:50 water: methanol. The calibration standards ranged from 0.5 to 75 mM for APAP glutathione and 0.25-75 mM for all the other analytes.
Analytical methods. All samples were analyzed by LC-MS/MS with a Waters ACQUITY Ultra-Performance Liquid Chromatography (UPLC) system interfaced by electrospray ionization with a Waters Quattro Premier XE triple quadrupole mass spectrometer (Waters Corp., Milford, Massachusetts) operated in positive mode with multiple reaction monitoring scan type. The following source conditions were applied: 3.0 kV for the capillary voltage, 120 C for the source temperature, 350 C for the desolvation temperature, 50 l/h for the source gas flow and 600 l/h for the desolvation gas flow. The following mass transitions and collision energies (CEs) were used to detect the respective analytes: The different compounds were separated on a Waters UPLC HSS T3 column (1.8 mm, 2.1 Â 150 mm) maintained at 50 C and using a gradient at 0.4 ml/min flow rate of mobile phase A (6 mM ammonium acetate in water with 0.01% formic acid) and mobile phase B (methanol) as follows: 2% B held for 0.5 min, increased to 75% over 3.5 min followed by an increase to 98% over 0.5 min and held at 98% for 2.0 min. APAP and its metabolites were quantified by back calculation of a weighted (1/Â), linear least squares regression. The regression fit used the analyte/internal standard peak area ratios calculated from the calibration. APAP-d 4 was used as the internal standard for APAP and APAP sulfate-d 3 was used as the internal standard for all the metabolites. The MS peaks were integrated using QuanLynx software (version 4.1, Waters Corp., Milford, Massachusetts).
Statistical Analysis
To determine statistical significance, we used 2-way ANOVA, which was calculated using the GraphPad Prism software. Values were considered statistically significant if p .05.
RESULTS
Increased O-GlcNAcylation in Livers After APAP Overdose Increase in total liver lysate protein O-GlcNAcylation was observed between 3 and 24 h after APAP treatment in all molecular weight proteins as indicated by Western blotting using a global O-GlcNAcylation antibody RL2, which can identify all O-GlcNAcylated proteins ( Figure 1B ). Increased in OGlcNAcylation correlates with increased liver injury as measured by serum ALT levels ( Figure 1C ). To further determine the role of O-GlcNAcylation in liver injury following APAP overdose, we generated hepatocyte-specific OGT KO mice as described in the "Materials and Methods" section. The deletion of OGT was confirmed by Western Blot analysis for total liver extracts ( Figure 1D ). A significant decrease in OGT and a concomitant decline in total O-GlcNAcylation were observed in OGT KO mice. Western blot analysis of OGT using isolated hepatocytes and nonparenchymal cells (NPCs) from the liver showed significant decrease in OGT protein specifically in hepatocytes and no change in NPCs (Supplementary Figure 1C) .
OGT KO Mice Are Resistant to APAP-Induced Acute Liver Injury
Wild-type (WT) and OGT KO mice were treated with 300 mg/kg APAP. Serum ALT levels indicated a significant decrease in liver injury at 6, 12, and 24-h post-APAP treatment in OGT KO mice compared with WT mice. These findings were corroborated by histopathological analysis by H&E staining ( Figure 2B ). WT mice showed extensive centrilobular necrosis as expected within 6 h after APAP exposure. The OGT KO mice exhibited a moderate change in hepatic histology but no frank cell death was observed based on the relationship between necrosis and ALT in the early stages of APAP-induced liver injury. Further, we determined changes in hepatic glycogen content using PAS staining in WT and OGT KO mice after APAP treatment. We did not observe any difference in hepatic glycogen content in un-fasted WT and OGT KO mice (Supplementary Figure 2) . After overnight fasting, a significant decrease in hepatic glycogen was observed in OGT KO mice as compared with control mice from the non-fasting stage. Interestingly, the hepatic glycogen content was replaced much faster (within 1 h) in OGT KO mice after APAP treatment as compared with control mice, where it took almost 24 h. These data coincide with kinetics of liver injury such that OGT KO mice, which have lower injury, have faster replenishment of hepatic glycogen.
OGT KO Mice Did Not Have Altered APAP Metabolism To determine whether the lower liver injury in the OGT KO mice is due to decreased APAP metabolism we determined hepatic CYP2E1 activity, APAP metabolite levels and adduct formation. There was no difference in microsomal CYP2E1 activity as measured by p-nitrophenol assay between WT and OGT KO mice ( Figure 3A) . Interestingly, we observed significantly less APAPprotein adducts at 1 and 6 h in the OGT KO mice as compared with WT mice ( Figure 3B ). We further analyzed the APAP metabolite profile using LC-MS, which showed that OGT KO and WT had similar levels of APAP-glucuronide and APAP-sulfate at 1 h, but those levels were significantly decreased in OGT KO mice at 6 and 12 h (Figs. 3C and 3D ). Hepatic JNK activation is a critical and indispensible step in APAP-induced liver injury (Du et al., 2015) . Western Blot analysis showed no increase in activation of JNK by phosphorylation (p-JNK) in OGT KO mice, but significant increase in JNK activation in WT mice ( Figure 3E ).
OGT KO Mice Had Rapid Replenishment of Hepatic Glutathione GSH is the main cellular antioxidant molecule that quenches NAPQI, the reactive metabolite of APAP, and scavenges mitochondrial ROS and peroxynitrite. We determined GSH levels over a time course of 0-24 h. Hepatic GSH levels were similar in OGT KO and WT mice at 0 h ( Figure 4A ). Further, both groups had similar depletion of GSH at 1 h after APAP treatment. However, the OGT KO mice had significantly higher and faster replenishment of GSH levels as compared with WT mice. The OGT KO mice regained baseline GSH level within 6 h after APAP treatment but the WT mice did not regain baseline GSH levels until 24-h post-APAP treatment ( Figure 4A ). To determine whether rapid GSH replenishment in OGT KO mice is due to induction of genes in the GSH biosynthesis pathway, we performed Real Time PCR for Glutamate-Cysteine ligase regulatory (GCLM) and catalytic (GCLC) subunits. The data indicate that both GCLM and GCLC were significantly increased in OGT KO mice compared with WT mice 1 and 6 h (Figs. 4B and 4C) . Furthermore, Glutathione reductase (GR), an enzyme important for the recycling of GSH from the disulfide (GSSG) form, was also significantly increased in OGT KO mice 1 and 6 h when compared with WT mice ( Figure 4D ).
TMG Increases O-GlcNAc Levels in Livers of APAP Treated Mice
Next, we determined the effect of increased O-GlcNAcylation on APAP toxicity. Preliminary dose finding studies indicated that 400 mg/kg of TMG was a suitable dose to induce hepatic OGlcNAcylation within 18 h (data not shown). Western blotting indicted that Male C57BL/6 J mice treated with 400 mg/kg dose of TMG 1.5 h after the administration of a 300 mg/kg dose of APAP (Supplementary Figure 1A) showed increased liver OGlcNAcylation as compared with mice treated with saline (Supplementary Figure 1B) . A moderate increase in OGlcNAcylation was observed at 6 h, which further increased at 12 and 24 h after APAP treatment (Supplementary Figure 1B) .
Increased APAP-Induced Liver Injury in Mice With Higher O-GlcNAc
Serum ALT levels and histopathological analysis of H&E-stained liver sections showed significantly higher APAP-induced liver injury following acute TMG treatment (Figs. 5A and 5B). Serum ALT was significantly increased following chronic TMG treatment at 24 h (Supplementary Figure 3A) . Both serum ALT activities ( Figure 5A ) and the areas of necrosis (Figs. 5B and 5C) were significantly higher in acute TMG-treated mice with increased O-GlcNAc levels at 6 and 12 h post-APAP administration. Liver injury decreased 24 h after APAP treatment in both control mice and in mice with increased O-GlcNAc levels as demonstrated by the decrease in serum ALT levels and improved histology.
Sustained Increase in Hepatic JNK Activation in Mice With Higher O-GlcNAc After APAP Treatment
We performed further analysis to determine the mechanisms of increased APAP-induced liver injury in mice with higher OGlcNAc levels. Western blot analyses revealed higher JNK activation (increased phosphorylation of JNK) in acute TMG-treated mice as compared with control mice at 6-and 12-h post-APAP administration. In control mice JNK activation peaked at 4 h and declined thereafter. However, in acute TMG-treated mice, JNK activation was prolonged at least until 12-h post-APAP treatment (Figs. 6A and 6B ). Further analysis revealed higher mitochondrial JNK activation in mice with higher O-GlcNAc at 9-h post-APAP treatment (data not shown).
No Change in APAP Metabolism After Acute TMG Treatment
To determine whether the increase in APAP-induced liver injury observed in mice with higher O-GlcNAc is due to increased APAP metabolism, we measured 3 factors indicative of APAP metabolism including hepatic CYP2E1 levels, GSH depletion and APAP adduct formation. Western blot analysis of total liver lysates obtained from mice treated with acute TMG only at 400 and 800 mg/kg indicated no change in CYP2E1 expression ( Figure 7A) . HPLC-based analysis of APAP-protein adducts showed an equal degree of protein adduct formation in control mice and in mice with higher O-GlcNAcylation due to acute TMG treatment after APAP treatment ( Figure 7B ). Analysis of hepatic GSH content revealed significant and similar GSH depletion in both control and acute TMG-treated mice following APAP treatment. However, a moderate delay in the recovery of hepatic GSH after APAP treatment was observed in acute TMGtreated mice between 6 and 12 h (Figure 7 C) . Consistent with these data, Real time PCR analysis showed significant reduction in transcripts of GCLC and GR at 12 h in acute TMG-treated mice (Figs. 7D and 7F ). GCLM transcript levels were moderately lower but the difference was not statistically significant ( Figure 7E ).
To determine the effect of TMG pretreatment on APAP toxicity, we developed a chronic TMG treatment model to induced O-GlcNAcylation. Male C57BL/6 J mice were treated with 50 mg/kg TMG for 2 weeks and were administered 300 mg/kg APAP 24 h after the last dose of TMG. Chronic treatment of TMG-treated mice had equal liver injury at 6 h but exhibited significantly higher liver injury at 24 h after APAP treatment (Supplementary Figure 3A) . Chronic TMG-treated mice showed small but significant increase in APAP adducts at 6-h post-APAP treatment (Supplementary Figure 3B) . Hepatic GSH depletion was significant after APAP treatment in both vehicle and chronic TMG-treated mice but GSH replenishment exhibited moderately lower GSH renewal in chronic TMG-treated mice (Supplementary Figure 3F) . There was no significant difference in GCLC, GCLM, or GR in chronic TMG-treated mice, but Figure 5 . Increased liver injury in mice with acute increased O-GlcNAc. A, Serum ALT levels in mice treated with APAP þ saline and APAP þ TMG at 4, 6, 12, and 24 h after APAP administration. *Indicates statistically significant difference at p < .05 between the groups at the same time point. B, Percent necrosis in mice treated with APAP þ saline and APAP þ 400 mg/kg TMG at 4, 6, 12, and 24 h after APAP administration. C, Representative photomicrographs of H&E-stained liver sections from APAP þ saline and APAP þ 400 mg/kg TMG-treated mice at 6, 12, and 24 h after APAP dose.
there was a trend towards an increase in GCLC and GCLM ( Supplementary Figs. 3C-E) .
DISCUSSION
Approximately 50% of all the ALF cases in many western countries are associated with overdose of APAP (Lee, 1993 (Lee, , 2003 Lee and Seremba, 2008) . Despite decades of research, the mechanisms of APAP-induced ALF are not completely clear . Hence the treatment options for APAP-induced ALF remain extremely limited (Chung et al., 2006; Larson et al., 2005) . Recent studies have demonstrated that PTM of proteins including sumoylation, lysine conjugation, methylation, ubiquitination, and O-GlcNAcylation play a central role in numerous pathophysiologies (Baker et al., 2017; Martinez et al., 2017; Osna et al., 2016; Schrattenholz et al., 2010) . In case of APAP-induced ALF, SIRT3-dependent protein deacetylation results in exacerbation of APAP-induced liver injury (Lu et al., 2011) . However, the role of many other PTMs in APAP-induced liver injury is currently not known. Here, we demonstrate that hepatic OGlcNAcylation plays a crucial role in APAP hepatotoxicity. Our data indicate that increase in hepatic O-GlcNAcylation of proteins results in increased APAP-induced liver injury and decreased O-GlcNAcylation inhibits APAP-induced liver injury. First, we used hepatocyte-specific OGT KO mice, which have significantly lower hepatic O-GlcNAcylation to study APAPinduced liver injury. The OGT KO mice displayed a significant reduction in liver injury when compared with WT mice. Consistently, when we increased hepatic O-GlcNAcylation using TMG-mediated OGA inhibition, APAP hepatotoxicity was exacerbated. These data suggest that O-GlcNAcylation plays a critical role in initiation of APAP-induced liver injury.
Cyp2E1 is the most important cytochrome P450 enzyme responsible for phase 2 metabolism of APAP . Our data showed that there was no difference in hepatic CYP2E1 expression (data not shown) or activity following OGT deletion. Further, no difference in basal GSH levels and the extent of GSH depletion after APAP treatment in WT and OGT KO mice was observed. However, APAP-protein adducts were decreased by approximately 50% in the OGT KO mice. The decrease in quantity of protein adducts in spite of equal CYP2E1 activity and basal GSH levels indicate that O-GlcNAcylated proteins may have higher susceptibility to forming APAP-protein adducts. These data are consistent with previous observations that protein modifications such as acetylation of lysine residues attenuated protein adduct formation and protected against APAP hepatotoxicity (Lu et al., 2011) . We also observed a marked decrease in hepatic glycogen content following fasting the OGT KO mice prior to APAP administration. Interestingly, the OGT KO mice were able to regain hepatic glycogen content within 1 h after APAP overdose, while it took almost 24 h for the WT mice to return to the pre-APAP treatment level of hepatic glycogen. These data suggest that rapid replenishment of hepatic glycogen may influence APAP adduct formation.
The major mechanism behind the protection observed in OGT KO mice was significantly faster GSH replenishment in OGT KO mice following APAP treatment. APAP-induced cell death is critically dependent on the mitochondrial oxidant stress and peroxynitrite formation after initial GSH depletion and protein adduct formation (Du et al., 2016) . The lack of GSH during this initial phase substantially impairs the antioxidant defense of the cell. Consequently, it was shown that providing substrates for GSH synthesis (N-acetylcysteine, GSH) during this time accelerates the GSH recovery in the cell, and most importantly in the mitochondria, protects against APAP-induced liver injury (James et al., 2003; Knight et al., 2002; Saito et al., 2010) . Moreover, female mice demonstrate a more pronounced induction of GCLC, the key enzyme in GSH biosynthesis, after APAP compared with male mice and the resulting faster recovery of hepatic GSH levels makes these female mice much less susceptible to APAP hepatotoxicity than male mice (Weimer et al., 2014) . On the other hand, overexpression of GCLC or GCLM in male mice also renders them less susceptible to APAP-induced liver injury (Botta et al., 2006 (Botta et al., , 2008 . Together, these data demonstrate the importance of the hepatic GSH synthesis capacity as a critical determinant of the susceptibility to APAP-induced hepatotoxicity. Our data indicate a significant up regulation of all 3 key enzymes in GSH metabolism including GCLM, GCLC, and GR in the OGT KO mice following APAP treatment. These findings explain the faster recovery of hepatic GSH levels and the resistance to APAP hepatotoxicity. It is known that the enzymes involved in GSH synthesis are regulated by the nuclear receptor Nrf2 (Enomoto et al., 2001; Wild and Mulcahy, 2000) , which plays a critical role in protection against oxidative stress in the liver. Interestingly, recently published data from other laboratories (Chen et al., 2017) and our group (Tan et al., 2017) have shown that Nrf2 is O-GlcNAcylated, and the treatment of mice with TMG leads to a loss of NRF2 expression while OGT KO animals have an increase in Nrf2 expression. Our data are consistent with this observation and suggest that deletion of OGT may reduce O-GlcNAcylation of Nrf2 resulting in increased protein and, as shown by target gene expression levels, in activity of Nrf2. Stabilization of Nrf2 may lead to a rapid induction in GSH biosynthesis genes, faster replenishment of GSH and restricting progression of APAP-induced liver injury. In the opposite condition, expression of GSH biosynthetic genes is down regulated in TMG-treated mice, which have higher OGlcNAcylation. Taken together, these data indicate that Nrf2 activity is regulated by O-GlcNAcylation, which in turn regulates GSH replenishment and the extent of APAP-induced liver injury.
It is known that APAP-induced liver injury involves a cascade of events following bio-activation of APAP to NAPQI including increased formation of reactive oxygen and reactive nitrogen species, JNK activation, mitochondrial damage, and Figure 7 . A, Western Blot analysis for CYP2E1 using total cell extracts from mice treated with 400 or 800 mg/kg TMG dose. (B) APAP protein adducts (C) Hepatic GSH levels and in the liver in control mice, mice treated with APAP þ saline and APAP þ 400 mg/kg TMG at 0, 4, 6, 12, and 24 h after APAP treatments. Real time PCR of GSH metabolism enzymes (D) GCLC, (E) GLCM, and (F) GR in mice treated with APAP þ 400 mg/kg TMG at 12 h. *Indicates statistically significant difference at p < .05 between the groups at the same time point. ultimately cellular necrosis (Jaeschke and Bajt, 2006; Jaeschke et al., 2012) . JNK is activated by phosphorylation at Thr183/ Tyr185 by upstream MAPK cascade (Seki et al., 2012) . Previous studies have shown that activation (phosphorylation) of JNK is a critical step in APAP-induced liver injury (Gunawan et al., 2006; Han et al., 2010; Henderson et al., 2007; McGill et al., 2012) . Our studies revealed that increasing hepatic O-GlcNAcylation after APAP overdose results in increased and prolonged JNK activation, which correlates with higher hepatic injury. Studies indicate that O-GlcNAcylation of proteins can both decrease and increase protein activity (Slawson and Hart, 2011) . It is possible that O-GlcNAcylation further induces hepatic JNK activation following APAP overdose and contributes to higher injury. Alternatively, O-GlcNAcylation could inhibit phosphatases that have been shown to reduce JNK activation (Mobasher et al., 2013; Wancket et al., 2012) .
Collectively, the data presented in this study are significant because chemicals that increase O-GlcNAcylation, and specifically TMG, are being tested as therapeutic agents for neurological disorders including Alzheimer's disease (Macauley and Vocadlo, 2010) . Another issue is potential interaction of APAP with the dietary supplement glucosamine. The availability of O-GlcNAc is controlled by flux through the hexosamine biosynthetic pathway (HBP) (Teo et al., 2010) . Glucose enters this pathway and is converted to UDP-GlcNAc, the metabolite for OGT. Glucosamine feeds directly into the HBP, skipping the initial step, and can result in increased O-GlcNAcylation. This is important because glucosamine is a popular dietary supplement used for its perceived benefits for arthritis and joint pain (Miller and Clegg, 2011) . The addition of glucosamine to a pain regimen that already includes APAP could potentially be hazardous. Our data suggests that any therapeutic interventions that increase O-GlcNAcylation should be carefully tested for its safety, drug-drug interactions and possible hepatotoxic effects while methods to decrease cellular O-GlcNAc might be promising new therapeutics targets for the treatment of APAP overdose and APAP-induced liver injury.
In conclusion, our data demonstrate that decreasing hepatic O-GlcNAcylation, a ubiquitous PTM of key proteins, drastically reduced the toxic effects of APAP by a dual effect. First, reduced OGlcNAcylation attenuates targets for protein adduct formation and second, the promotion of GSH recovery enhances the scavenging capacity for ROS and peroxynitrite in mitochondria. These studies have revealed a novel pathway that critically affects not only APAP-induced liver injury but also highlighted a possible causal role of O-GlcNAcylation in drug-and chemical-induced liver injury where oxidative stress is a major mechanism.
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